PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA ...
PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in ...
PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, ...
Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized ...
Accessibility Tools